You just read:

Avillion Advances Co-development Programme with Merck: IND Now Open for Phase 2 Study of M1095, an Anti-IL-17 A/F Nanobody® in Psoriasis

News provided by

Avillion LLP

16 Feb, 2018, 09:00 GMT